Illumina, Inc. (NASDAQ:ILMN) Stock Has Consensus Target Price of $219.69

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given an average rating of “Hold” by the eighteen ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $225.94.

ILMN has been the topic of a number of recent research reports. Guggenheim increased their price target on shares of Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Barclays lifted their price target on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research note on Wednesday, October 7th. Leerink Partners boosted their price objective on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Argus upped their price objective on shares of Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Finally, Citigroup upped their price objective on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. The trade was a 16.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Signal Advisors Wealth LLC bought a new stake in shares of Illumina in the 3rd quarter worth approximately $325,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of Illumina during the third quarter valued at approximately $425,000. McCollum Christoferson Group LLC purchased a new position in shares of Illumina during the third quarter valued at approximately $285,000. NorthCrest Asset Manangement LLC raised its holdings in shares of Illumina by 2.7% during the third quarter. NorthCrest Asset Manangement LLC now owns 8,357 shares of the life sciences company’s stock valued at $2,211,000 after acquiring an additional 220 shares in the last quarter. Finally, DWR Wealth Management LLC bought a new position in shares of Illumina during the third quarter valued at approximately $228,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

ILMN opened at $271.17 on Wednesday. The stock has a 50-day moving average price of $230.11 and a 200-day moving average price of $183.38. Illumina has a 12-month low of $88.00 and a 12-month high of $309.35. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $40.95 billion, a P/E ratio of 53.72, a PEG ratio of 3.92 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The company’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts predict that Illumina will post 5.36 earnings per share for the current fiscal year.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s new SpliceAI2 genomic model is drawing attention because it could strengthen the company’s clinical-genomics narrative and expand the potential applications of its sequencing data and AI tools. Investors may view the launch as evidence that Illumina is moving beyond instruments and consumables toward higher-value software and clinical insights. Did Illumina’s New SpliceAI2 Genomic Model Just Reframe Its Clinical Genomics Narrative?
• Positive Sentiment: Analysts expect Illumina’s sequencing business to continue recovering, supported by improving demand and recent AI developments. The company’s latest reported quarter exceeded consensus revenue and earnings estimates, while full-year 2026 EPS guidance remains $5.30–$5.40. Illumina’s Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?
• Neutral Sentiment: Illumina entered a new dealer agreement intended to support financing. The arrangement may help sales execution or customer purchasing, but the available announcement provides limited detail on its expected financial impact. Illumina Establishes New Dealer Agreement to Support Financing
• Negative Sentiment: Illumina has initiated a voluntary global Class II recall involving certain NovaSeq 6000Dx and NextSeq 550Dx diagnostic systems. Approximately 80 units are affected because of a security vulnerability in associated DRAGEN servers. The issue reportedly concerns server configuration rather than sequencing accuracy or core hardware, limiting the direct product-risk implications but still creating remediation, customer-confidence and compliance concerns. Illumina Starts Global Recall of Diagnostic Sequencers Over Security Vulnerability
• Negative Sentiment: After a roughly 191% one-year rally, valuation-focused commentary suggests ILMN may be near fair value, leaving less room for execution mistakes. Investors are increasingly demanding that the sequencing recovery and AI push translate into sustained cash-flow growth, while upcoming third-quarter results could become a near-term catalyst. Illumina Stock May Be About Fair Value After Genomics AI Launch

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.